Lilly’s Donanemab Delay: Labeling, Real-World Operationalization May Be Reason For Adcomm

 
• By Sarah Karlin-Smith
  
document with "delayed" stamped on it
Lilly's donanemab approval for Alzheimer's is delayed due to last minute advisory committee • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers